Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 21;11:3609–3617. doi: 10.2147/OTT.S165723

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Zhao and Wu. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

SPL-A sensitizes human endometrial carcinoma cells to TRAIL-mediated apoptosis.

Notes: Human endometrial carcinoma cell lines HEC-1A and RL-952 were treated with SPL-A alone, TRAIL alone, or SPL-A plus TRAIL for 24 h. (A) The sub-G1 fraction was analyzed by FCM analysis. (B) Western blot analysis of cleaved PARP. β-actin was loading control. (C) Ishikawa cells were treated with different concentrations of SPL-A. Western blot analysis of c-FLIP, Bcl-2, Bcl-xL, Mcl-1, cIAP1, and XIAP. β-actin was loading control. The results are shown as mean ± SD (n=5). *p<0.05 compared to SPL-A alone or TRAIL alone.

Abbreviations: FCM, flow cytometry; SPL-A, spindlactone A.